Kite Study Director
Kite, A Gilead Company
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
38
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers
0
PubMed author-name match
Trials
Studies that name Kite Study Director as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:26 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07903506 · To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaKite, A Gilead Company · not yet recruiting · Newly Diagnosed Multiple Myeloma · study director
- Ph3NCT07887672 · A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaKite, A Gilead Company · not yet recruiting · Newly Diagnosed Multiple Myeloma · study chair
- Ph3NCT07479797 · Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyKite, A Gilead Company · active not recruiting · Relapsed or Refractory Large B-cell Lymphoma · study director
- Ph1NCT07304154 · Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual TreatmentKite, A Gilead Company · recruiting · Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis, Multiple Sclerosis · study director
- Ph1NCT07038447 · A Study of KITE-363 in Participants With Refractory Autoimmune DiseasesKite, A Gilead Company · enrolling by invitation · Systemic Lupus Erythematosus, Lupus Nephritis, Systemic Sclerosis · study director
- Ph1NCT06626919 · Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesKite, A Gilead Company · recruiting · Muscular Diseases, Neuromuscular Manifestations, Autoimmune · study director
- Ph1NCT06539338 · A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous TreatmentKite, A Gilead Company · active not recruiting · Lymphomas Non-Hodgkin's B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma · study director
- Ph3NCT06413498 · A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaKite, A Gilead Company · active not recruiting · Multiple Myeloma · study director
- Ph2NCT06253663 · Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaKite, A Gilead Company · active not recruiting · Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia · study director
- Ph1NCT06079164 · Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell LymphomaKite, A Gilead Company · active not recruiting · Relapsed/Refractory Large B-cell Lymphoma · study director
- N/ANCT05776160 · Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelKite, A Gilead Company · available · Large B-cell Lymphoma, Follicular Lymphoma · study director
- N/ANCT05776134 · Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene AutoleucelKite, A Gilead Company · available · Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia · study director
- Ph3NCT05605899 · Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell LymphomaKite, A Gilead Company · active not recruiting · High-risk Large B-cell Lymphoma (LBCL) · study director
- Ph2NCT05537766 · Study of Brexucabtagene Autoleucel in Adults With Rare B-cell MalignanciesKite, A Gilead Company · terminated · Relapsed/Refractory Waldenstrom Macroglobulinemia, Relapsed/Refractory Richter Transformation, Relapsed/Refractory Burkitt Lymphoma · study director
- Ph2NCT05459571 · Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell LymphomaKite, A Gilead Company · completed · Relapsed or Refractory Large B-cell Lymphoma · study director
- Ph1NCT05457010 · Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.Kite, A Gilead Company · active not recruiting · Acute Myeloid Leukemia, Myelodysplastic Syndromes · study director
- Ph3NCT05371093 · Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaKite, A Gilead Company · active not recruiting · Relapsed/Refractory Follicular Lymphoma · study director
- N/ANCT05041309 · Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite StudiesKite, A Gilead Company · enrolling by invitation · Solid and Hematological Malignancies, Autoimmune Diseases · study director
- Ph1/Ph2NCT04989803 · Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell LymphomaKite, A Gilead Company · active not recruiting · Relapsed and/or Refractory B-cell Lymphoma · study director
- Ph2NCT04880434 · Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)Kite, A Gilead Company · completed · Relapsed/Refractory Mantle Cell Lymphoma · study director
- Ph1NCT04789408 · Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid LeukemiaKite, A Gilead Company · terminated · Acute Myeloid Leukemia · study director
- Ph1NCT04314843 · Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell LymphomaKite, A Gilead Company · terminated · Relapsed/Refractory Large B-cell Lymphoma · study director
- N/ANCT04162756 · Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell MalignanciesKite, A Gilead Company · approved for marketing · Relapse/Refractory Mantle Cell Lymphoma · study director
- Ph2NCT04002401 · Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaKite, A Gilead Company · completed · Refractory Large B-cell Lymphoma · study director
- Ph1NCT03912831 · Study to Evaluate the Safety and Efficacy of KITE-439 in HLA-A*02:01+ Adults With Relapsed/Refractory HPV16+ CancersGilead Sciences · terminated · Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer · study director
- Ph2NCT03761056 · Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell LymphomaKite, A Gilead Company · completed · B-cell Lymphoma · study director
- Ph1NCT03704298 · Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell LymphomaKite, A Gilead Company · terminated · Relapsed/Refractory Large B-cell Lymphoma · study director
- Ph1NCT03624036 · Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaKite, A Gilead Company · terminated · Relapsed/Refractory Chronic Lymphocytic Leukemia and Relapsed/Refractory Small Lymphocytic Lymphoma · study director
- Ph3NCT03391466 · Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell LymphomaKite, A Gilead Company · completed · Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) · study director
- Ph1NCT03318861 · Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple MyelomaKite, A Gilead Company · terminated · Relapsed/Refractory Multiple Myeloma · study director
- N/ANCT03153462 · Axicabtagene Ciloleucel Expanded Access StudyKite, A Gilead Company · approved for marketing · Relapsed/Refractory Diffuse Large B Cell Lymphoma, Relapsed/Refractory Primary Mediastinal B Cell Lymphoma, Relapsed/Refractory Transformed Follicular Lymphoma · study director
- Ph1NCT03139370 · Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced CancersKite, A Gilead Company · terminated · Solid Tumor · study director
- Ph2NCT03105336 · A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin LymphomaKite, A Gilead Company · completed · Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma · study director
- Ph1/Ph2NCT02926833 · Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Kite, A Gilead Company · completed · Refractory Diffuse Large B Cell Lymphoma · study director
- Ph1/Ph2NCT02625480 · Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin LymphomaKite, A Gilead Company · completed · Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma · study director
- Ph1/Ph2NCT02614066 · A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)Kite, A Gilead Company · completed · Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia · study director
- Ph2NCT02601313 · Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)Kite, A Gilead Company · completed · Relapsed/Refractory Mantle Cell Lymphoma · study director
- Ph1/Ph2NCT02348216 · Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin LymphomaKite, A Gilead Company · completed · Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL) · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:26 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.